Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Hormonal Regulation01:40

Hormonal Regulation

Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation of prolactin levels with the neutrophil/lymphocyte ratio.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2021
Same author

Differences in the neutrophil/lymphocyte ratio and the platelet/lymphocyte ratio in pregnant women with and without COVID-19.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2021
Same author

[Ocular changes after hormone replacement therapy in postmenopausal women. A preliminary report].

Ginecologia y obstetricia de Mexico·2011
Same author

[Virilizing adrenal adenoma: a report of a case].

Ginecologia y obstetricia de Mexico·2011
Same author

[Frequency of metabolic syndrome in Mexican postmenopausal women and its relation with the hormonal therapy].

Ginecologia y obstetricia de Mexico·2009
Same author

[Levels of estradiol and serum testosterone in healthy postmenopausal women and its relationship with symptoms].

Ginecologia y obstetricia de Mexico·2009

Related Experiment Video

Updated: Jun 30, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
08:46

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

[Low-dose hormonal therapy during climacteric].

Sebastián Carranza Lira1

  • 1Unidad Mèdica de Alta Especialidad, Hospital de Ginecoobstetricia Luis Castelazo Ayala, IMSS, México DF. scarranzal@mexis.com

Ginecologia Y Obstetricia De Mexico
|September 19, 2008
PubMed
Summary

Low-dose hormone therapy is recommended for managing menopausal vasomotor symptoms. This review highlights the benefits and safety of low and ultra-low doses as a baseline treatment for symptomatic women.

Area of Science:

  • Reproductive endocrinology
  • Menopause management
  • Hormone therapy research

Context:

  • Hormone therapy (HT) use during climacteric has evolved significantly.
  • The Women's Health Initiative (WHI) study prompted a reevaluation of HT safety and indications.
  • Current consensus supports HT primarily for vasomotor symptom control.

Purpose:

  • To review the literature on low-dose and ultra-low-dose hormone therapy for climacteric women.
  • To evaluate the benefits and risks associated with reduced HT dosages.
  • To establish low-dose HT as a baseline treatment option.

Summary:

  • Low-dose and ultra-low-dose hormone therapy demonstrate benefits for managing menopausal symptoms.
  • Reduced dosages are associated with lower risks compared to conventional doses.

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Experiment Videos

Last Updated: Jun 30, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
08:46

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

  • This review synthesizes evidence supporting these lower-risk HT options.

    • Impact:

    • Provides evidence for considering low-dose hormone therapy as a primary treatment for symptomatic menopausal women.
    • Informs clinical practice regarding safer hormone therapy alternatives.
    • Contributes to the ongoing discussion on optimizing hormone therapy for women's health.